Pharmaceutical Followers
Peter Arcidiacono, Paul B. Ellickson, Peter Landry, David B. Ridley
We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show generics and ``me-too'' drugs each increased consumer welfare more than $100 million in 2010, holding insurance premiums constant. However, insurance payments in 2010 fell by nearly $1 billion due to generics and rose by over $7 billion due to me-too antiulcer drugs
Year of publication: |
October 2013
|
---|---|
Authors: | Arcidiacono, Peter |
Other Persons: | Ridley, David B. (contributor) ; Landry, Peter (contributor) ; Ellickson, Paul B. (contributor) |
Institutions: | National Bureau of Economic Research (contributor) |
Publisher: |
Cambridge, Mass : National Bureau of Economic Research |
Subject: | Gesundheitskosten | Health care costs | Imitationsstrategie | Imitation strategy | Arzneimittel | Pharmaceuticals | Generika | Generic drugs | Gesetzliche Krankenversicherung | Public health insurance |
Saved in:
freely available
Extent: | 1 Online-Ressource |
---|---|
Series: | NBER working paper series ; no. w19522 |
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Mode of access: World Wide Web System requirements: Adobe [Acrobat] Reader required for PDF files Hardcopy version available to institutional subscribers. |
Other identifiers: | 10.3386/w19522 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10012459141